April 25 (Reuters) - The U.S. Food and Drug Administration on Thursday sent a warning letter to Cardinal Health after an inspection of its facility in Illinois showed that the company was marketing unapproved devices. (Reporting by Pratik Jain in Bengaluru)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
99.12 USD | -0.42% | +0.89% | -1.32% |
May. 07 | Cardinal Health Board of Directors Approves Increase to Quarterly Dividend, Payable on July 15, 2024 | CI |
May. 07 | Deutsche Bank Adjusts Price Target on Cardinal Health to $110 From $116 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.32% | 24.24B | |
+21.06% | 72.78B | |
+8.80% | 8.59B | |
+8.25% | 8.38B | |
-19.42% | 8.09B | |
+6.65% | 4.81B | |
+16.83% | 4.32B | |
-1.83% | 4.05B | |
-2.82% | 3.93B | |
+26.97% | 3.79B |
- Stock Market
- Equities
- CAH Stock
- News Cardinal Health, Inc.
- US FDA sends warning to Cardinal Health for marketing unapproved devices